ArticleJournal of laboratory physicians
Epidemiology of carbapenem-resistant Enterobacteriaceae in a Tertiary Care Center in the Kingdom of Bahrain.
Article in Journal of laboratory physicians. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- Carbapenem-Resistant Gram-Negative Bacilli in Mauritania: A Major Public Health Threat.MicrobiologyOpen · 2026Article
- Molecular Analysis of Tigecycline Resistance in Carbapenem-Resistant Enterobacterales (CRE) in Mthatha and Surrounding Hospitals.Antibiotics (Basel, Switzerland) · 2025Article
- Prevalence of Carbapenemase Production Among Klebsiella and Escherichia coli Isolated From Urinary Tract Infections.Cureus · 2024Article
- A review of colistin-resistantArchives of Razi Institute · 2024Review
- Epidemiology and clinical characteristics of patients with carbapenem-resistant enterobacterales infections: experience from a large tertiary care center in a developing country.BMC infectious diseases · 2023Article
- Clinical characteristics of carbapenem-resistantBMJ open · 2023Article
- High Frequency ofInfection & chemotherapy · 2023Article
- Prevalence and genetic characterization of clinically relevant extended-spectrum β-lactamase-producingFrontiers in antibiotics · 2023Review
- Early Years of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Extended Spectrum- and Carbapenemase-Based β-Lactam Resistance in the Arabian Peninsula-A Descriptive Review of Recent Years.Antibiotics (Basel, Switzerland) · 2022Review
- Clinical carbapenem-resistantFrontiers in cellular and infection microbiology · 2022Article
- Detection of Colistin Resistance in Carbapenem Resistant Enterobacteriaceae by Reference Broth Microdilution and Comparative Evaluation of Three Other Methods.Journal of laboratory physicians · 2021Article
- Carbapenem-ResistantInfection and drug resistance · 2020Article
- Evaluation of Resistance Mechanisms in Carbapenem-ResistantInfection and drug resistance · 2020Article
- Antimicrobial Resistance in Bacterial Pathogens and Detection of Carbapenemases inAntibiotics (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of the study is to estimate the rate of infection with carbapenem-resistant MATERIALS AND
methodsAll clinical samples with positive growth of CRE over 6-year period (January 2012-December 2017) were collected from the microbiology laboratory data.
resultsThe CRE incidence was high in the first half of study period (2012-2014) and then decreased between 2015 and 2017, after implementation of intensified CRE control measure bundle. About 49.4% of CRE-positive samples were isolated from the elderly age group (above 65 years old), most of them were admitted in the intensive care unit (ICU). The most common isolated organisms were
conclusionElderly population and ICU admission were important risk factors for CRE acquisition. Most of CRE isolates were sensitive to both colistin and tigecycline, which make them the best combination for empiric frontline therapy for suspected serious CRE infection in our facility. Implementing CRE-bundled infection control measures significantly reduced the incidence of CRE infection in our hospital.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.